. Pneumocystis carinii pneumonia (PCP) affects over 50% of patients with AIDS. DL-alpha-difluoromethylornithine (DFMO, eflornithine), an inhibitor of one key enzyme of polyamine biosynthesis, has been used as an alternative treatment for PCP. While DFMO is less toxic than most PCP therapies, efficacy is also lower so that it is not currently considered as a therapy for this disease. New tools have been developed in this laboratory for studies of P. carinii and for studies of polyamine metabolism. Interpretation of data collected with these tools led to the hypothesis that one reason DFMO is selectively toxic to P. carinii is that, unlike mammalian cells, P. carinii does not regulate polyamine catabolism. Another interpretation led to the prediction that DFMO would be most effective when administered as a continuos infusion, a prediction confirmed in an animal model. Further information on P. carinii polyamine metabolism can be expected to lead to new improvements including identification of other metabolic targets within polyamine metabolism. The following studies will be performed. The mechanism of DFMO-induced rapid polyamine depletion will be determined by studying excretion of polyamines and by characterizing the catabolic and salvage enzymes spermidine/spermine acetyl transferase (SSAT) and polyamine oxidase (PAO), respectively. The dynamics of P. carinii polyamine metabolism will be studied with emphasis on the relative importance of de novo polyamine biosynthesis vs scavenge of polyamines from the host. Polyamine transporter (s) and biosynthetic enzymes will be characterized. A panel of compounds which have been shown to modulate polyamine metabolism in other cells will be used as probes of P. carinii polyamine metabolism. These compounds will also be studied for their ability to manipulate polyamine transport and metabolism as well as for their ability to inhibit P. carinii growth in vitro.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI041947-01A1
Application #
2543377
Study Section
AIDS and Related Research Study Section 5 (ARRE)
Project Start
1998-01-01
Project End
2000-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
New York University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Clarkson Jr, A B; Turkel-Parrella, D; Williams, J H et al. (2001) Action of deferoxamine against Pneumocystis carinii. Antimicrob Agents Chemother 45:3560-5
Merali, S; Vargas, D; Franklin, M et al. (2000) S-adenosylmethionine and Pneumocystis carinii. J Biol Chem 275:14958-63
Merali, S; Saric, M; Chin, K et al. (2000) Effect of a bis-benzyl polyamine analogue on Pneumocystis carinii. Antimicrob Agents Chemother 44:337-43
Merali, S (1999) Pneumocystis carinii polyamine catabolism. J Biol Chem 274:21017-22